Cadila Healthcare - Experimental Drug Copper Histidinate Approval Prospects High And Can Be A Decent Opportunity: Nirmal Bang
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Nirmal Bang Report
Cadila Healthcare Ltd. recently announced the acquisition of experimental drug – CUTX-101 (copper histidinate) from Cyprium for treating the Menkes disease.
Menkes disease is a genetic paediatric disorder caused by gene mutations of copper transporter ATP7A.
CUTX-101 is currently in Phase 3 development and as per the agreement terms, Cadila will make an upfront cash payment of $20 million to Cyprium.
The company will also provide additional cash payments upon achievement of certain regulatory milestones, besides paying royalties and commercial milestone payments based on the net sales of CUTX-101.
Depending on the sales level, royalties will range between mid-single-digit to mid-twenties as a percentage of sales.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.